Posts by: Jose Marques Lopes, PhD

News

A Phase 3 clinical trial of treatment candidate AMT-061 for severe and moderately severe hemophilia B has treated its first patient. The open-label HOPE-B study (NCT03569891) is testing the safety ... Read more

January 21, 2019January 21, 2019

Activities and Levels of Bleeding Risk They May Carry Ranked by Physical Therapists

News

Repetitive movements, fitness level, and prolonged and competitive physical activity are among the factors that raise bleeding risks for people with hemophilia taking part in such activities, a study based ... Read more

December 12, 2018December 12, 2018

Eloctate and Alprolix Show Long-Term Effectiveness for Hemophilia in Extension Studies

News

Treatment of severe hemophilia A with Eloctate and hemophilia B with Alprolix was safe and improved the patients’ annualized bleed rates (ABRs) over four years, according to the results of two extension studies ... Read more

November 26, 2018November 26, 2018

Potential Gene Therapy for Hemophilia A, AMT-180, May Treat Patients Regardless of Inhibitor Status, uniQure Says

News

A gene therapy from uniQure in early testing, called AMT-180, has the the potential to treat all hemophilia A patients, including those with inhibitors, according to the company. Hemophilia A is caused ... Read more

November 12, 2018November 12, 2018

Patient Enrollment Ongoing in Phase 3 Trial of AMT-061 for Hemophilia B, uniQure Says in Update

News

uniQure is continuing to enroll participants for its global Phase 3 trial (NCT03569891) testing the potential gene therapy AMT-061 in men with severe or moderately severe hemophilia B, according to an ... Read more

October 15, 2018October 15, 2018

Rate of Total Joint Replacement Similar in Hemophilia A and B, Study Reports

News

Total joint replacement (TJR) is more common in severe hemophilia patients requiring more frequent treatment, according to a population-based study in Taiwan. The findings also revealed that the incidence ... Read more

July 25, 2018July 25, 2018

The Assistance Fund Offers New Program to Help Hemophilia Patients with Medical Expenses

News

Hemophilia patients may now benefit from financial assistance for out-of-pocket expenses, health insurance premiums, and incidental medical costs following the launch of a new program from The Assistance Fund (TAF). ... Read more

June 25, 2018June 25, 2018

Oxidation of FVIII Increases Immune Response in Hemophilia A Mouse Model, Study Finds

News

Oxidation of clotting protein factor VIII (FVIII) increased the immune response to the replacement therapy in a mouse model of severe hemophilia A, a study found. Conducted by researchers ... Read more

June 22, 2018June 22, 2018

Developing Inhibitors Inflates Treatment Costs and Impairs Quality of Life, Study Finds

News

Hemophilia patients who develop inhibitors against treatment face markedly higher healthcare costs — about three times those of other patients — and experience poorer quality of life, according to a ... Read more

May 30, 2018May 30, 2018

BIVV001 Extends Lifetime of Hemophilia A Replacement Therapy, Early Trial Data Shows

News

Preliminary results of a Phase 1/2a trial of the hemophilia A experimental treatment BIVV001 show a significant extension of replacement therapy lifetime in the blood, Bioverativ announced. The ongoing, and ... Read more

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

First Patient Treated in Phase 3 Trial of AMT-061 in Hemophilia B

Activities and Levels of Bleeding Risk They May Carry Ranked by Physical Therapists

Eloctate and Alprolix Show Long-Term Effectiveness for Hemophilia in Extension Studies

Potential Gene Therapy for Hemophilia A, AMT-180, May Treat Patients Regardless of Inhibitor Status, uniQure Says

Patient Enrollment Ongoing in Phase 3 Trial of AMT-061 for Hemophilia B, uniQure Says in Update

Rate of Total Joint Replacement Similar in Hemophilia A and B, Study Reports

The Assistance Fund Offers New Program to Help Hemophilia Patients with Medical Expenses

Oxidation of FVIII Increases Immune Response in Hemophilia A Mouse Model, Study Finds

Developing Inhibitors Inflates Treatment Costs and Impairs Quality of Life, Study Finds

BIVV001 Extends Lifetime of Hemophilia A Replacement Therapy, Early Trial Data Shows

Pin It on Pinterest